Yahoo Finance

UPDATE: Pfizer Achieves Primary Endpoint With Phase 3B Top-Line Results Of GENOTROPIN® In Very Young Children Born Small For Gestational Age

Pfizer Inc. (NYSE: PFE) announced today the top-line results from a Phase 3B study evaluating the 24-month efficacy of GENOTROPIN® (somatropin) on the height in small-for-gestational-age (SGA) ...
News Medical

Genotropin MiniQuick

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. GENOTROPIN MiniQuick is a syringe containing a single dose of ...
Business Wire

Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study evaluating ...
Healthline

Genotropin (Somatropin) Cost and Financial Assistance

The price you pay for Genotropin may depend on factors such as the form you use, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the ...
Pharmabiz

Pfizer, OPKO announce phase 3 C0311002 study of Genotropin to treat children with growth hormone deficiency meets primary endpoints

Pfizer and OPKO Health announced that C0311002, a phase 3, randomized, multicenter, open-label, crossover study evaluating somatrogon dosed once-weekly in children 3 to <18 years of age with growth ...
Business Wire

US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the US Food and Drug Administration (FDA) has accepted for filing the initial ...
Pharmabiz

Pfizer, Opko’s Ngenla to treat paediatric growth hormone deficiency receives Japanese approval

Pfizer Japan Inc. and Opko Health, Inc. announced that the next generation long-acting growth hormone injection, Ngenla (somatrogon) Inj. 24 mg Pens and 60 mg Pens, has been approved by the Ministry ...
Yahoo Finance

Japan’s MHLW Approves Pfizer and OPKO’s NGENLA® (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency

TOKYO and MIAMI, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Pfizer Japan Inc. and OPKO Health, Inc. (NASDAQ: OPK) announced today that the next generation long-acting growth hormone injection, NGENLA ® ...
Nasdaq

Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency

NEW YORK & MIAMI--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the next-generation ...
Nasdaq

FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

New, longer-acting treatment offers option to reduce the frequency of injections for children with growth hormone deficiency from daily to once-weekly Growth hormone deficiency (GHD) is a rare disease ...